Lymphoma News

Active systemic cancer treatment did not appear associated with increased mortality among patients with cancer and COVID-19, according to study results published in JAMA Network Open.

CHICAGO — Second-line therapy with lisocabtagene maraleucel induced initial complete remission among more than half of patients with relapsed or refractory transplant-ineligible large B-cell lymphoma, results from a phase 2 trial showed.

Men, older patients and patients with low income were among those with elevated risk for CVD hospitalization prior to receiving a diagnosis of potentially curable cancer, researchers reported.

Risks for severe maternal morbidity and mortality appeared higher among pregnancies complicated by cancer, according to study results in a research letter published in JAMA Oncology.

Vaccinated patients with cancer had significantly higher risks for breakthrough COVID-19 infection, especially those undergoing active cancer care, compared with individuals without cancer, according to a study published in JAMA Oncology.

The addition of bortezomib to chemotherapy significantly improved survival outcomes among children and young adults with T-cell lymphoblastic lymphoma, according to phase 3 study results published in Journal of Clinical Oncology.

CHICAGO – Healio gathered the best, brightest and boldest group of oncologists during the ASCO Annual Meeting in Chicago to celebrate our inaugural Healio Disruptive Innovators.

A phase 2/phase 3 study assessed intramuscular asparaginase Erwinia chrysanthemi (recombinant)-rywn for patients with acute lymphoblastic leukemia or lymphoblastic lymphoma who developed hypersensitivity to E. coli-derived L-asparaginase.

The FDA granted regenerative medicine advanced therapy designation to ALLO-501, a chimeric antigen receptor T-cell therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma.

One of the major challenges in the field of nanomedicine is translating in vitro performance of nanoparticles to in vivo studies, a factor that may hinder the development of nanoparticles as drug delivery vehicles.